Current Report Filing (8-k)
June 15 2016 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2016 (June 9, 2016)
Alnylam Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36407
|
|
77-0602661
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
300 Third Street, Cambridge, MA
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617) 551-8200
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal
Officers; Compensatory Arrangements of Certain Officers.
On June 9, 2016, the Board of Directors of Alnylam Pharmaceuticals, Inc. (the
Company) appointed David-Alexandre C. Gros, M.D., the Companys Senior Vice President and Chief Business Officer, to serve as the Companys principal financial officer, succeeding Michael P. Mason in such role, effective as of
July 1, 2016. Dr. Gros is responsible for the Companys finance, business development, corporate communications and investor relations functions. Mr. Mason, the Companys Vice President, Finance and Treasurer, will continue
to serve in that position and as the Companys principal accounting officer, leading the Companys finance operations.
Dr. Gros, 43, has
served as the Companys Senior Vice President and Chief Business Officer since June 8, 2015. Prior to joining the Company, Dr. Gros served as Executive Vice President and Chief Strategy Officer at Sanofi SA, from September 2011 to
June 2015, where he was a member of the Executive Committee and the Global Leadership Team. Prior to Sanofi, he held positions of increasing responsibility in investment banking at Centerview Partners from 2009 to July 2011 and Merrill Lynch from
2006 to 2009, and in management consulting at McKinsey & Company prior to that time.
Dr. Gros compensation is described in the
Companys Proxy Statement for the year ended December 31, 2015 filed with the Securities and Exchange Commission on March 17, 2016. The changes reported in this Current Report on Form 8-K did not result in any change in compensation
for Dr. Gros or Mr. Mason.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ALNYLAM PHARMACEUTICALS, INC.
|
|
|
|
|
Date: June 15, 2016
|
|
|
|
By:
|
|
/s/ John M. Maraganore, Ph.D.
|
|
|
|
|
|
|
John M. Maraganore, Ph.D.
Chief Executive
Officer
|
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024